Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-gamma for Sepsis-induced Immunoparalysis
NCT01649921Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2012
- Primary completion
- Dec 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Interferon-gamma with Placebo (2 arms). Primary endpoint: Tumor Necrosis Factor-alpha secretion by ex vivo LPS-stimulated leukocytes at Day 28. Started Nov 2012; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT01649921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649921.